Suman-Chauhan N, Meecham K G, Webdale L, Hunter J C, Pritchard M C, Woodruff G N, Hill D R
Parke Davis Neuroscience Research Centre, Cambridge University Forvie Site, UK.
Regul Pept. 1996 Aug 27;65(1):37-43. doi: 10.1016/0167-0115(96)00070-5.
The novel radioligand [3H]PD140376 was used to label receptors that bind cholecystokinin (CCK) and related peptides in membranes prepared from guinea-pig brain and gastric glands. Under control conditions, measurements of the apparent affinity of 11 agonist and 16 antagonist ligands in both tissues revealed a strong positive relationship between the affinity of a compound in either tissue (slope of the regression line = 0.89, r2 = 0.908). Agonists consistently showed higher affinity for sites in gastric glands compared to brain. If agonists were excluded from the analysis, the degree of correspondence between affinities measured in each tissue was almost perfect (slope = 0.93, r2 = 0.986). In the presence of the guanyl nucleotide 5'-guanylimidodiphosphate (GppNHp), agonist affinity in gastric glands, but not brain, was reduced such that there was a direct relationship between binding affinity in each tissue. These data are consistent with the notion that the receptor sites in brain and gastric glands, which recognise CCK and gastrin related compounds, are the same and of the CCK-B/gastrin subtype. The receptors in the two respective tissues, however, do appear to differ in the degree of post-receptor coupling. These findings may explain previously reported differences between gastrin and CCK-B receptors that were based upon binding studies using agonist ligands.
新型放射性配体[³H]PD140376用于标记豚鼠脑和胃腺制备的膜中与胆囊收缩素(CCK)及相关肽结合的受体。在对照条件下,对两种组织中11种激动剂和16种拮抗剂配体的表观亲和力进行测量,结果显示任一组织中化合物的亲和力之间存在很强的正相关关系(回归线斜率=0.89,r²=0.908)。与脑相比,激动剂对胃腺中的位点始终表现出更高的亲和力。如果在分析中排除激动剂,那么在每个组织中测得的亲和力之间的对应程度几乎是完美的(斜率=0.93,r²=0.986)。在鸟苷酸5'-鸟苷亚氨基二磷酸(GppNHp)存在的情况下,胃腺而非脑中的激动剂亲和力降低,从而使得每个组织中的结合亲和力之间存在直接关系。这些数据与以下观点一致,即脑和胃腺中识别CCK和胃泌素相关化合物的受体位点是相同的,且属于CCK-B/胃泌素亚型。然而,两个组织中的受体在受体后偶联程度上似乎确实存在差异。这些发现可能解释了先前报道的基于使用激动剂配体的结合研究得出的胃泌素和CCK-B受体之间的差异。